Plaque Psoriasis

This interview featured a discussion with Dr. Lim on his team’s findings regarding the effects of infrared radiation on human skin.

Positive results from REMIX-1 and REMIX-2 on remilbrutinib could mean the beginning of a new class of chronic spontaneous urticaria therapy in about a decade.

This new data from the UK suggests possible opportunities for preventing anxiety and depression for those with eczema or psoriasis by addressing modifiable risk factors such as sleep.

This study’s findings demonstrate the necessity of risk factor identification for atopic-like dermatitis, as well as the importance of exploring alternative treatments for severe cases.

The data from this analysis indicates that for those with psoriasis, effective and long-term continuous control of the skin disease could diminish risk of CCVD risk.

The data from this new study may indicate home NBUVB treatment effectiveness and other benefits such as financial, convenience, and medical benefits.

In this interview with Dr. Gold, she describes her team’s recent findings from a phase 4 head-to-head study on risankizumab for psoriasis patients.

This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.

Brad Glick, DO, MPH; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, comment on the future of plaque psoriasis treatment and share clinical pearls on the management of plaque psoriasis.

Expert dermatologists comment on the use of nonsteroidal topical therapies in the treatment of plaque psoriasis and how it has affected clinical practice.

Experts discuss the DERMIS clinical trials of roflumilast in the treatment of plaque psoriasis, highlighting its efficacy in the intertriginous areas.

This new data on factors which may inhibit access to dermatologic care indicates the potential value for policy-makers as well as educators to make changes to fill such gaps in care.

Mona Shahriari, MD, and Linda Stein Gold, MD, review the long-term safety and efficacy data of tapinarof as well as its use in clinical practice for the management of plaque psoriasis.

Experts in dermatology discuss recent advances in the plaque psoriasis treatment toolbox, highlighting the mechanism of action and data of tapinarof.

This new data indicates that while it is not a physically limiting disease, alopecia areata can substantially affect patients’ lives on an individual and national level.

This new data highlights the need to address certain sociocultural, socioeconomic, and environmental factors that can more strongly affect individuals in minority groups.

The study’s findings bring major lessons for dermatologists to light, the most apparent of which being that many reasons for discordance between clinicians and patients may be modified.

This segment of her interview with HCPLive featured a discussion with Ferris on the FRONTIER 1 phase 2b trial results and their implications for psoriasis patients.

New phase 2b data from the FRONTIER 1 study showed promise for what could become the first and only oral IL-23 antagonist peptide for psoriasis.

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.

This new data indicated the strong safety profile and efficacy of CAL/BDP-cream using PAD technology for psoriasis patients, and could lead to better adherence and outcomes in real-world settings.

This systematic review and meta-analysis demonstrated the potential effectiveness of JAK inhibitors for alopecia, though further trials are needed for long-term use.

Mona Shahriari, MD, reviews the efficacy data of topical treatments in the treatment of plaque psoriasis, and Linda Stein Gold, MD, discusses unmet needs in the plaque psoriasis treatment landscape.

Experts share the difference between the remittive and the suppressive effect in plaque psoriasis and how to get patients there.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.